Guardion Health Sciences (GHSI) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 14, 2021
Cover [Abstract]
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	0001642375
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,426,993
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 43,329,674	$ 8,518,732
Accounts receivable	64,897	11,248
Inventories	288,527	384,972
Prepaid expenses	312,523	179,931
Total current assets	43,995,621	9,094,883
Deposits	11,751	11,751
Property and equipment, net	265,978	285,676
Right of use asset, net	379,120	418,590
Intangible assets	50,000	50,000
Total assets	44,702,470	9,860,900
Current liabilities
Accounts payable	230,403	608,313
Accrued expenses	518,826	127,637
Payable to former officer	67,708	148,958
Derivative warrant liability		25,978
Operating lease liability - current	165,757	162,845
Total current liabilities	982,694	1,073,731
Operating lease liability - long-term	229,430	271,903
Total liabilities	1,212,124	1,345,634
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value; 250,000,000 shares authorized; 24,426,993 and 15,170,628 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	24,427	15,171
Additional paid-in capital	100,192,794	62,583,423
Accumulated deficit	(56,726,875)	(54,083,328)
Total stockholders' equity	43,490,346	8,515,266
Total liabilities and stockholders' equity	$ 44,702,470	$ 9,860,900

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	24,426,993	15,170,628
Common stock, shares outstanding	24,426,993	15,170,628

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Total revenue	$ 233,297	$ 245,723
Cost of goods sold
Total cost of goods sold	133,015	109,108
Gross profit	100,282	136,615
Operating expenses
Research and development	20,608	31,188
Sales and marketing	457,727	488,846
General and administrative	2,291,472	1,952,803
Total operating expenses	2,769,807	2,472,837
Loss from operations	(2,669,525)	(2,336,222)
Other expenses:
Interest expense		(1,747)
Change in fair value of derivative liability		(8,944)
Total other expenses		(10,691)
Net loss	$ (2,669,525)	$ (2,346,913)
Net loss per common share - basic and diluted	$ (0.13)	$ (0.18)
Weighted average common shares outstanding - basic and diluted	21,351,380	13,105,061
Medical Foods [Member]
Revenue
Total revenue	$ 162,143	$ 139,789
Cost of goods sold
Total cost of goods sold	84,917	66,196
Medical Devices [Member]
Revenue
Total revenue	71,154	91,190
Cost of goods sold
Total cost of goods sold	48,098	40,642
Other [Member]
Revenue
Total revenue		14,744
Cost of goods sold
Total cost of goods sold		$ 2,270

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019	$ 12,497	$ 57,531,014	$ (45,511,671)	$ 12,031,840
Balance, shares at Dec. 31, 2019	12,497,094
Fair value of vested stock options - officer and director		436,287		(436,287)
Fair value of vested stock options		55,281		55,281
Fair value of common stock issued for services	$ 25	12,300		12,325
Fair value of common stock issued for services, shares	4,167
Common stock issued upon exercise of warrants	$ 10,382	3,540,399		3,550,781
Common stock issued upon exercise of warrants, shares	1,730,400
Net loss			(2,346,913)	(2,346,913)
Balance at Mar. 31, 2020	$ 22,904	61,575,281	(47,858,584)	13,739,601
Balance, shares at Mar. 31, 2020	14,231,661
Balance at Dec. 31, 2020	$ 15,171	62,583,423	(54,083,328)	8,515,266
Balance, shares at Dec. 31, 2020	15,170,628
Cumulative effect adjustment from the impact of adoption of Accounting Standards Update (ASU) 2020-06 related to warrants (See Notes 2 and 7)			25,978	25,978
Fair value of vested stock options - officer and director
Fair value of vested stock options		205,772		205,772
Fair value of common stock issued for services		181,843		181,843
Common stock issued for cash, net of offering costs	$ 7,608	33,654,989		33,662,597
Common stock issued for cash, net of offering costs, shares	7,608,674
Common stock issued upon exercise of warrants	$ 1,648	3,566,767		3,568,415
Common stock issued upon exercise of warrants, shares	1,647,691
Net loss			(2,669,525)	(2,669,525)
Balance at Mar. 31, 2021	$ 24,427	$ 100,192,794	$ (56,726,875)	$ 43,490,346
Balance, shares at Mar. 31, 2021	24,426,993

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Activities
Net loss	$ (2,669,525)	$ (2,346,913)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,698	23,114
Amortization of operating lease right-of-use asset	39,470	37,983
Fair value of vested stock options	205,772	55,281
Fair value of common stock issued for services	181,843	12,325
Fair value of vested stock options - officer and director		436,287
Change in fair value of derivative liability		8,944
(Increase) / decrease:
Accounts receivable	(53,649)	47,255
Inventories	96,445	(131,195)
Prepaid expenses	(132,592)	(568,199)
Increase / (decrease):
Accounts payable	(377,910)	179,093
Customer deposit		437,500
Operating lease liability	(39,561)	(36,803)
Accrued expenses	391,189	109,918
Payable to former officer	(81,250)
Net cash used in operating activities	(2,420,070)	(1,735,410)
Investing Activities
Purchase of property and equipment		(40,733)
Net cash used in investing activities		(40,733)
Financing Activities
Proceeds from sale of common stock, net	33,662,597
Proceeds from exercise of warrants	3,568,415	3,550,781
Net cash provided by financing activities	37,231,012	3,550,781
Cash:
Net increase	34,810,942	1,774,638
Balance at beginning of period	8,518,732	11,115,502
Balance at end of period	43,329,674	12,890,140
Supplemental disclosure of cash flow information:
Cash paid for - Income taxes	9,355
Non-cash financing activities:
Reclassification of prepaid costs to inventory		308,178
Reclass of equipment sold from property and equipment to equipment held for sale		$ 8,771

Organization and Business Opera

Organization and Business Operations	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Business Guardion Health Sciences, Inc. (the “Company”) is a specialty health sciences company (1) that has developed medical foods and medical devices in the ocular health space and (2) that is developing nutraceuticals that the Company believes will provide supportive health benefits to consumers. The Company has been primarily engaged in research and development, product commercialization and capital raising activities. The Company was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. Liquidity The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. For the three months ended March 31, 2021, the Company incurred a net loss of $2,669,525 and used cash in operating activities of $2,420,070. At March 31, 2021, the Company had cash on hand of $43,329,674 and working capital of $43,012,927. Notwithstanding the net loss for 2021, management believes that its current cash balance is sufficient to fund operations for at least the next twelve months. The Company expects to continue to incur net losses and negative operating cash flows in the near-term and will continue to incur significant expenses for development and commercialization of its medical foods and medical devices, and the successful development and commercialization of any new products or product lines. The Company may also utilize cash to fund acquisitions. The Company may seek to raise additional debt and/or equity capital to fund future operations and strategic initiatives, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. Over time, if the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations. COVID-19 The Company is subject to risks and uncertainties of the COVID-19 pandemic that could adversely impact our business. The Company has implemented additional health and safety precautions and protocols in response to the pandemic and government guidelines, including curtailing employee travel and working from its executive offices, with many employees continuing their work remotely. During 2020 and the first quarter of 2021, sales of certain products remained flat, as many eye doctor offices were closed, or operating with limited capacity, due to COVID-19 related orders. During 2020 and through the first quarter of 2021, we did not experience a jeopardization of our supply chain due to the COVID-19 outbreak. The extent of the impact of the COVID-19 pandemic has had and will continue to have on the Company’s business is highly uncertain and difficult to predict and quantify. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, including vaccination efforts, as well as the economic impact on local, regional, national and international markets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2021. Reverse Stock Split On March 1, 2021, following stockholder and board approval, the Company effectuated a 1-for-6 reverse split of its outstanding shares of common stock, without any change to its par value. The authorized number of shares of common stock were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, as all fractional shares were rounded up to the next whole share. Accordingly, all share and per share amounts presented herein with respect to common stock have been retroactively adjusted to reflect the above-described reverse stock split for all periods presented. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, VectorVision Ocular Health, Inc., NutriGuard Formulations, Inc., and Transcranial Doppler Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from those estimates. Revenue Recognition The Company generates its revenue from two business segments: ● Medical Foods and Nutraceuticals Segment ● Medical Devices Segment The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers All products sold by the Company are distinct individual products and are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. Revenues by segment: Three Months Ended March 31, 2021 2020 Medical foods and nutraceuticals $ 162,143 $ 139,789 Medical devices 71,154 91,190 Other - 14,744 Total $ 233,297 $ 245,723 The Company’s Medical Foods and Nutraceuticals revenues earned during the three months ended March 31, 2021 and 2020 are derived from individual retail customers in North America. Medical Device revenues are derived from a worldwide customer base consisting of both retail customers and distributors. Sales to distributors were approximately 25% and 2% of total revenues for the three months ended March 31, 2021 and 2020, respectively. Revenues by geographical area: Three Months Ended March 31, 2021 2020 North America $ 172,140 $ 234,354 Asia 58,262 2,800 Europe & Other 2,895 8,569 Total $ 233,297 $ 245,723 Concentrations During the three months ended March 31, 2021, one customer accounted for approximately 25% of the Company’s sales. No other customer accounted for more than 10% of such sales in either the 2021 or 2020 three-month periods. Cash balances are maintained at large, well-established financial institutions. At times, cash balances exceed federally insured limits. Insurance coverage limits are $250,000 per depositor at each financial institution. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of its assessment of the creditworthiness and financial viability of the financial institutions that hold such cash balances. Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s Medical Foods and Nutraceuticals and related products. Research and development expenditures are expensed as incurred and totaled $20,608 and $31,188 for the three months ended March 31, 2021 and 2020, respectively. Patent Costs The Company is the owner of four issued domestic patents, two pending domestic patent applications, one issued foreign patent in Europe and the United Kingdom, two issued foreign patents in Ireland, and one issued foreign patent in Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the three months ended March 31, 2021 and 2020, patent costs were $24,297 and $27,181, respectively, and are included in general and administrative costs in the statements of operations. Stock-Based Compensation The Company periodically issues stock-based compensation to employees and non-employees in non-capital raising transactions for services and for financing costs. Such grants vest and expire according to terms established at the issuance date. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Loss per Common Share Basic loss per share is computed by dividing net loss by the weighted-average common shares outstanding during a period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include shares from unexercised warrants and options. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and options are anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: March 31, 2021 2020 Warrants 485,067 3,065,056 Options 930,867 542,084 1,415,934 3,607,140 Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1 - Level 2 - Level 3 - The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. As of March 31, 2021, and December 31, 2020, the Company’s balance sheets included Level 2 liabilities comprised of the fair value of warrant liabilities aggregating $0 and $25,978, respectively (See Note 7). Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). At December 31, 2020, the Company had recorded a derivative liability of $25,978 related to 10,417 warrants issued in 2019 because the settlement provisions of the warrants contained language that the shares underlying the warrants are required to be registered. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach. ASU 2020-06 removed the requirement to consider if the warrants would be settled in registered shares, and accordingly, the adoption of ASU 2020-06 resulted in a decrease to accumulated deficit of $25,978 and a decrease in derivative warrant liability of $25,978 on January 1, 2021. In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As a smaller reporting company, ASU 2016-13 will be effective for us beginning January 1, 2023, with early adoption permitted. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures. Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	3. Inventories Inventories consisted of the following: March 31, December 31, 2021 2020 Raw materials $ 57,264 $ 218,307 Finished goods 231,263 166,665 $ 288,527 $ 384,972 The Company’s inventories are stated at the lower of cost or net realizable value on a FIFO basis. During the quarter ended March 31, 2021 the Company recorded an inventory write down of approximately $6,000 related to raw materials inventory.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, net Property and equipment consisted of the following: March 31, December 31, 2021 2020 Leasehold improvements $ 103,255 $ 103,255 Testing equipment 348,124 348,124 Furniture and fixtures 197,349 197,349 Computer equipment 68,460 68,460 Office equipment 9,835 9,835 727,023 727,023 Less accumulated depreciation and amortization (461,045 ) (441,347 ) $ 265,978 $ 285,676 For the three months ended March 31, 2021 and 2020, depreciation and amortization expense was $19,698 and $23,114, respectively.

Operating Leases

Operating Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Operating Leases	5. Operating Leases The Company leases its office and certain warehouse space under two operating leases. The Company accounts for its leases under ASC 842, Leases. As of December 31, 2020, the Company’s net right of use asset totaled $418,590. During the three months ended March 31, 2021, the Company recorded amortization of right-of-use asset of $39,470. At March 31, 2021, the net right-of-use assets was $379,120. As of December 31, 2020, the Company’s operating lease liabilities totaled $434,748. During the three months ended March 31, 2021, the Company made payments of $39,561 towards the operating lease liability. As of March 31, 2021, the operating lease liabilities totaled $395,187. As of March 31, 2021, the weighted average remaining lease terms for operating leases are 2.25 years, and the weighted average discount rate for operating lease is 4.6%. Future minimum lease payments under the leases are as follows: Year ending Operating Leases Remainder of 2021 $ 131,033 2022 182,249 2023 98,417 Total lease payments 411,699 Less: Imputed interest/present value discount (16,512 ) Present value of lease liabilities 395,187 Less: Current portion (165,757 ) $ 229,430

Payable to Former Officer

Payable to Former Officer	3 Months Ended
	Mar. 31, 2021
Payable To Former Officer
Payable to Former Officer	6. Payable to Former Officer Effective June 15, 2020, Michael Favish resigned as Chief Executive Officer of the Company and resigned from the Company’s Board of Directors. Terms of the settlement agreement between the parties included the continuation of his previous salary of $325,000 during the twelve months subsequent to his resignation. The $325,000 of aggregate settlement payments was recorded in costs related to resignation of former officer expense in the consolidated statements of operations in the quarter ended June 30, 2020. As of March 31, 2021, $67,708 of the amount due remains accrued on our consolidated balance sheet and is payable through June 15, 2021.

Derivative Liability

Derivative Liability	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	7. Derivative Liability On April 9, 2019, the Company issued 10,417 warrants with an exercise price of $30.00 per share. The Company accounted for the conversion feature of these warrants as a derivative liability because the settlement provisions contained language that the shares underlying the warrants are required to be registered. The fair value of the warrants is remeasured at each reporting period, and the change in the fair value is recognized in earnings in the accompanying Statements of Operations. At December 31, 2020, the Company had recorded a derivative liability of $25,978 related to the 10,417 warrants issued in 2019. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach. ASU 2020-06 removed the requirement to consider if the warrants would be settled in registered shares, and accordingly, the adoption of ASU 2020-06 resulted in a decrease to accumulated deficit of $25,978 and a decrease in derivative warrant liability of $25,978 on January 1, 2021. The fair value of the warrant liability was determined at the following reporting dates using the Black-Scholes-Merton option pricing model and the following assumptions: Warrant Liability December 31, 2020 Stock price $ 2.49 Risk free interest rate 0.17 % Expected volatility 148 % Expected life in years 3.8 Expected dividend yield 0 % Number of warrants 10,417 Fair value of warrants $ 25,978

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Common Stock January 2021 and February 2021 At the Market Offerings On January 8, 2021, the Company entered into a sales agreement with Maxim Group LLC and filed a prospectus supplement pursuant to which the Company could sell up to $10,000,000 worth of shares of our common stock in an “at the market” offering through the distribution agent (the “January 2021 1st ATM Offering”). The offer and sale of the shares was made pursuant to a shelf registration statement on Form S-3 and the related prospectus filed by the Company with the Securities and Exchange Commission and declared effective by the SEC on September 24, 2020. The Company agreed to pay Maxim a commission equal to 3.0% of the aggregate gross proceeds from each sale of shares. On January 15, 2021, the Company completed the January 2021 1st ATM Offering, pursuant to which the Company sold an aggregate of 2,559,834 shares of its common stock and raised net proceeds (after deduction for sales commissions) of approximately $9,700,000. On January 28, 2021, the Company entered into a sales agreement with Maxim Group LLC and filed a prospectus supplement pursuant to which the Company could sell up to $25,000,000 worth of shares of our common stock in an “at the market” offering through the distribution agent (the “January 2021 2nd ATM Offering”). On February 10, 2021, the Company completed the January 2021 2nd ATM Offering, pursuant to which the Company sold an aggregate of 5,006,900 shares of its common stock and raised net proceeds (after deduction for sales commissions) of approximately $24,250,000. The Company incurred costs related to these financings of approximately $327,000 which is reflected as a reduction to the proceeds from the shares issued. The net cash received from both offerings after all expenses were approximately $33,623,000. Nasdaq Compliance As previously noted in the Company’s Form 10-K for the fiscal year ended December 31, 2020, on September 20, 2019, the Company received notice from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the previous 30 consecutive business days, the Company no longer satisfied the requirement to maintain a minimum bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Company originally had until March 18, 2020, to regain compliance with the Bid Price Rule; however, Nasdaq granted an extension until November 30, 2020. The Company was unable to regain compliance with the Bid Price Rule by November 30, 2020. Accordingly, on December 1, 2020, the Company received a letter from the Staff notifying it that its Common Stock would be subject to delisting from Nasdaq unless the Company timely appealed Nasdaq’s determination to a Nasdaq Listing Qualifications Panel (the “Panel”). The Company timely appealed Nasdaq’s determination to the Panel. On January 26, 2021, the Company received written notification that the Panel granted the Company an extension for continued listing through March 15, 2021. On March 1, 2021, the Company implemented the Reverse Stock Split (see Note 1) in an effort to regain compliance with the Bid Price Rule. Following the Reverse Stock Split mentioned above, on March 15, 2021, the Company received a letter from the Staff notifying it that it had regained compliance with the Bid Price Rule. The letter stated the staff had determined that for the prior 10 consecutive business days, from March 1, 2021 to March 12, 2021, the closing bid price of the Company’s common stock had been at $1.00 per share or greater and that accordingly, the Company had regained compliance with the Bid Price Rule, and that the matter was closed. Warrants A summary of the Company’s warrant activity is as follows: Shares Weighted Weighted December 31, 2020 2,132,758 $ 2.48 3.81 Granted - - - Forfeitures - - - Expirations - - - Exercised (1,647,691 ) 2.26 - March 31, 2021, all exercisable 485,067 $ 2.71 3.56 The exercise prices of warrants outstanding and exercisable as of March 31, 2021 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 160,108 $ 2.05 146,667 2.67 112,001 3.30 37,700 3.51 28,591 17.25 485,067 During the three months ended March 31, 2021, investors exercised a total of 1,647,691 warrants for 1,647,691 shares of common stock. The warrants were exercisable for an average price of $2.17 per share, which resulted in cash proceeds to the Company of $3,568,415. As of March 31, 2021, the Company had an aggregate of 485,067 outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $2.71 and a weighted average remaining life of 3.56 years. Stock Options A summary of the Company’s stock option activity is as follows: Shares Weighted Weighted December 31, 2020 778,196 9.48 6.38 Granted 152,671 3.95 9.80 Forfeitures - - - Expirations - - - Exercised - - - March 31, 2021, outstanding 930,867 $ 8.48 6.60 March 31, 2021, exercisable 479,932 $ 10.92 4.70 The exercise prices of options outstanding and exercisable as of March 31, 2021 are as follows: Options Outstanding (Shares) Exercise Prices 41,667 $ 1.48 5,001 1.91 41,667 2.33 1,667 2.46 16,667 3.25 152,671 3.95 375,000 6.00 104,167 12.00 69,445 13.20 10,415 13.80 112,500 15.00 930,867 During the three months ended March 31, 2021, the Company granted options to purchase 152,671 shares of common stock to the Company’s CEO with a grant date fair value of $514,171 using a Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 119%, (ii) discount rate of 0.38%, (iii) zero expected dividend yield, and (iv) expected life of 6 years. The options have an exercise price of $3.95 per share. 50,891 of the options will vest on the one-year anniversary of the grant date and the remaining options will vest on monthly basis over two years. The Company’s volatility is based on an average volatility of similar companies in the same industry. The risk-free interest rate was based on rates established by the Federal Reserve Bank. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. The expected life of the stock options granted is estimated using the “simplified” method, whereby the expected term equals the average of the vesting term and the original contract. During the three months ended March 31, 2021 and 2020, we recognized stock-compensation expense related to the fair value of vested stock options of $205,772 and $491,568, respectively, which was recorded in general and administrative expense. As of March 31, 2021, the Company had an aggregate of 450,935 remaining unvested options outstanding, with a remaining fair value of $911,444, to be amortized over a weighted average remaining life of 9.34 years. The aggregate intrinsic value of options outstanding as of March 31, 2021 was $43,293. Restricted Common Stock In January 2021, the Company granted 152,671 shares of the Company’s common stock with vesting terms to the Company’s CEO. The shares vest on the first anniversary of the award. If the CEO’s employment with the Company is terminated for any reason, any shares not then vested will be forfeited. Also effective in January 2021, the Company granted 41,667 shares of the Company’s common stock with vesting terms to a consultant for services. 4,167 of the shares vested immediately and the balance of 37,500 shares vesting through August 15, 2021. In the event the consultant’s service with the Company terminates, any shares not then vested will be forfeited. The total fair value of the 194,338 shares was determined to be $662,412 based on the price per shares of the Company’s common stock on the dates granted. The Company accounts for the share awards using the straight-line attribution or graded vesting method over the requisite service period provided that the amount of compensation cost recognized at any date is no less than the portion of the grant-date fair value of the award that is vested at that date. During the three months ended March 31, 2021, total share-based expense recognized related to vested restricted shares totaled $181,843. At March 31, 2021, there was $480,569 of unvested compensation related to these awards that will be amortized over a remaining vesting period of 3.7 years. The following table summarizes restricted common stock activity for the three months ended March 31, 2021: Number of shares Non-vested shares, December 31, 2020 - $ - Granted 194,338 662,412 Vested (22,917 ) (181,843 ) Forfeited - - Non-vested shares, March 31, 2021 171,421 $ 480,569

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions Dr. David Evans, interim chief executive officer of the Company from June 12, 2020 to January 6, 2021, together with his spouse, wholly owns Ceatus Media Group LLC (“Ceatus”) and DWT Evans LLC (“DWT”). For the three months ended March 31, 2021 and 2020, the Company paid Ceatus $22,500 and $38,000, respectively, for services related to digital marketing for the Company. The Company’s wholly owned subsidiary, VectorVision Ocular Health, leases office and warehouse space from DWT. For the three months ended March 31, 2021 and 2020, the Company paid DWT rent in the amounts of $5,571 and $5,307, respectively. In 2017, the Company acquired VectorVision, Inc. from David Evans, and also acquired AcQviz from Dr. Evans, which is a patented methodology for auto-calibrating and standardizing the testing light level for computer generated vision testing systems. Dr. Evans is entitled to receive a royalty on net revenue from AcQviz. As part of the development of the CSV-2000, AcQviz was embedded in the product by Radiant Technologies, Inc. in exchange for a 3% royalty on the sales of AcQviz. Radiant Technologies is owned by Joseph T. Evans, the brother of Dr. David Evans. During the three months ended March 31, 2021 and 2020, the Company did not incur any royalties due to net revenue from AcQviz.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Reporting	10. Segment Reporting The Company determined its reporting units in accordance with ASC 280, “Segment Reporting”. The Company currently operates in two reportable segments: Medical Foods and Nutraceuticals and Medical Devices. The Medical Foods and Nutraceuticals segment provides a portfolio of science-based, clinically supported nutrition, medical foods, and supplements. The Medical Devices segment includes a portfolio of medical diagnostic devices currently focused on the ocular space and contrast testing. The Company’s medical devices and accessories are used to measure visual function and certain anatomical features of the eye that detect early disease and monitor changes over time. The segments are based on the discrete financial information reviewed by the Chief Executive Officer, who is the Company’s Chief Operating Decision Maker (“CODM”), to make resource allocation decisions and to evaluate performance. The reportable segments are each managed separately because they manufacture and distribute distinct products or provide services with different processes. All reported segment revenues are derived from external customers. The accounting policies of the Company’s reportable segments are the same as those described in the summary of significant accounting policies (see Note 2). Certain corporate general and administrative expenses, including general overhead functions such as information systems, accounting, human resources, Board of Director fees, corporate legal fees, other compliance costs and certain administrative expenses, as well as interest and tax expense, are not allocated to the segments. The following tables set forth our results of operations by segment: For the Three Months Ended March 31, 2021 Corporate Medical Foods and Nutraceuticals Medical Devices Total Revenue $ - $ 162,143 $ 71,154 $ 233,297 Cost of goods sold - 84,917 48,098 133,015 Gross profit - 77,226 23,056 100,282 Stock compensation expense 387,615 - - 387,615 Operating expenses 1,150,600 1,176,127 55,465 2,382,192 Loss from operations $ (1,538,215 ) $ (1,098,901 ) $ (32,409 ) $ (2,669,525 ) For the Three Months Ended March 31, 2020 Corporate Medical Foods and Nutraceuticals Medical Devices Total Revenue $ 14,744 $ 139,789 $ 91,190 $ 245,723 Cost of goods sold - 78,439 30,669 109,108 Gross profit 14,744 61,350 60,521 136,615 Stock compensation expense 503,893 - - 503,893 Operating expenses 915,552 937,123 116,269 1,968,944 Loss from operations $ (1,404,701 ) $ (875,773 ) $ (55,748 ) $ (2,336,222 ) The following tables set forth our total assets by segment. Intersegment balances and transactions have been removed: As of March 31, 2021 Corporate Medical Foods and Nutraceuticals Medical Devices Total Current assets Cash $ 43,329,674 $ - $ - $ 43,329,674 Inventories - 194,081 94,446 288,527 Other - 224,660 152,759 377,419 Total current assets 43,329,674 418,741 247,205 43,995,620 Right of use asset, net - 339,873 39,247 379,120 Property and equipment, net - 125,158 140,821 265,979 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 43,329,674 $ 945,523 $ 427,273 $ 44,702,470 As of December 31, 2020 Corporate Medical Foods and Nutraceuticals Medical Devices Total Current assets Cash $ 8,518,732 $ - $ - $ 8,518,732 Inventories - 254,879 130,093 384,972 Other - 89,333 101,846 191,179 Total current assets 8,518,732 344,212 231,939 9,094,883 Right of use asset - 374,447 44,143 418,590 Property and equipment, net - 135,641 150,035 285,676 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 8,518,732 $ 916,051 $ 426,117 $ 9,860,900

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s financial statements at March 31, 2021 with respect to such matters. Effective January 6, 2021, the Board of Directors appointed Bret Scholtes as President, Chief Executive Officer, and as a director of the Company. The Company and Mr. Scholtes entered into an employment agreement pursuant to which Mr. Scholtes’ annual base salary is $400,000. The employment agreement provides that Mr. Scholtes shall have an annual target cash bonus of no less than $400,000 based on performance objectives determined by the Board of Directors. Additionally, Mr. Scholtes shall be granted (i) stock options equal to 2% of the Company’s issued and outstanding shares of common stock on the date of grant if the Company achieves specified performance objectives established by the Board for the Company’s fiscal years ending December 31, 2021, and December 31, 2022, and (ii) additional stock options equal to either 2% or 3% of the Company’s issued and outstanding shares of common stock on the date of grant if the Company meets certain financial objectives during the first five years following January 6, 2021. If Mr. Scholtes’ employment is terminated by the Company without cause, as defined, if the term expires after a notice of non-renewal is delivered by the Company, or if Mr. Scholtes’ employment is terminated following a change of control, as defined, Mr. Scholtes will be entitled to (a) twelve months’ base salary, (b) the prorated portion of the any bonus, based on actual performance, and (c) base salary and benefits accrued through the date of termination.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events The Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2021.
Reverse Stock Split	Reverse Stock Split On March 1, 2021, following stockholder and board approval, the Company effectuated a 1-for-6 reverse split of its outstanding shares of common stock, without any change to its par value. The authorized number of shares of common stock were not affected by the reverse stock split. No fractional shares were issued in connection with the reverse stock split, as all fractional shares were rounded up to the next whole share. Accordingly, all share and per share amounts presented herein with respect to common stock have been retroactively adjusted to reflect the above-described reverse stock split for all periods presented.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, VectorVision Ocular Health, Inc., NutriGuard Formulations, Inc., and Transcranial Doppler Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company generates its revenue from two business segments: ● Medical Foods and Nutraceuticals Segment ● Medical Devices Segment The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers All products sold by the Company are distinct individual products and are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. Revenues by segment: Three Months Ended March 31, 2021 2020 Medical foods and nutraceuticals $ 162,143 $ 139,789 Medical devices 71,154 91,190 Other - 14,744 Total $ 233,297 $ 245,723 The Company’s Medical Foods and Nutraceuticals revenues earned during the three months ended March 31, 2021 and 2020 are derived from individual retail customers in North America. Medical Device revenues are derived from a worldwide customer base consisting of both retail customers and distributors. Sales to distributors were approximately 25% and 2% of total revenues for the three months ended March 31, 2021 and 2020, respectively. Revenues by geographical area: Three Months Ended March 31, 2021 2020 North America $ 172,140 $ 234,354 Asia 58,262 2,800 Europe & Other 2,895 8,569 Total $ 233,297 $ 245,723
Concentrations	Concentrations During the three months ended March 31, 2021, one customer accounted for approximately 25% of the Company’s sales. No other customer accounted for more than 10% of such sales in either the 2021 or 2020 three-month periods. Cash balances are maintained at large, well-established financial institutions. At times, cash balances exceed federally insured limits. Insurance coverage limits are $250,000 per depositor at each financial institution. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of its assessment of the creditworthiness and financial viability of the financial institutions that hold such cash balances.
Research and Development Costs	Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s Medical Foods and Nutraceuticals and related products. Research and development expenditures are expensed as incurred and totaled $20,608 and $31,188 for the three months ended March 31, 2021 and 2020, respectively.
Patent Costs	Patent Costs The Company is the owner of four issued domestic patents, two pending domestic patent applications, one issued foreign patent in Europe and the United Kingdom, two issued foreign patents in Ireland, and one issued foreign patent in Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the three months ended March 31, 2021 and 2020, patent costs were $24,297 and $27,181, respectively, and are included in general and administrative costs in the statements of operations.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock-based compensation to employees and non-employees in non-capital raising transactions for services and for financing costs. Such grants vest and expire according to terms established at the issuance date. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.
Loss per Common Share	Loss per Common Share Basic loss per share is computed by dividing net loss by the weighted-average common shares outstanding during a period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include shares from unexercised warrants and options. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and options are anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: March 31, 2021 2020 Warrants 485,067 3,065,056 Options 930,867 542,084 1,415,934 3,607,140
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1 - Level 2 - Level 3 - The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. As of March 31, 2021, and December 31, 2020, the Company’s balance sheets included Level 2 liabilities comprised of the fair value of warrant liabilities aggregating $0 and $25,978, respectively (See Note 7).
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). At December 31, 2020, the Company had recorded a derivative liability of $25,978 related to 10,417 warrants issued in 2019 because the settlement provisions of the warrants contained language that the shares underlying the warrants are required to be registered. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach. ASU 2020-06 removed the requirement to consider if the warrants would be settled in registered shares, and accordingly, the adoption of ASU 2020-06 resulted in a decrease to accumulated deficit of $25,978 and a decrease in derivative warrant liability of $25,978 on January 1, 2021. In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As a smaller reporting company, ASU 2016-13 will be effective for us beginning January 1, 2023, with early adoption permitted. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures. Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of Revenues by Segment	Revenues by segment: Three Months Ended March 31, 2021 2020 Medical foods and nutraceuticals $ 162,143 $ 139,789 Medical devices 71,154 91,190 Other - 14,744 Total $ 233,297 $ 245,723
Schedule of Revenue by Geographical Area	Revenues by geographical area: Three Months Ended March 31, 2021 2020 North America $ 172,140 $ 234,354 Asia 58,262 2,800 Europe & Other 2,895 8,569 Total $ 233,297 $ 245,723
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: March 31, 2021 2020 Warrants 485,067 3,065,056 Options 930,867 542,084 1,415,934 3,607,140

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following: March 31, December 31, 2021 2020 Raw materials $ 57,264 $ 218,307 Finished goods 231,263 166,665 $ 288,527 $ 384,972

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: March 31, December 31, 2021 2020 Leasehold improvements $ 103,255 $ 103,255 Testing equipment 348,124 348,124 Furniture and fixtures 197,349 197,349 Computer equipment 68,460 68,460 Office equipment 9,835 9,835 727,023 727,023 Less accumulated depreciation and amortization (461,045 ) (441,347 ) $ 265,978 $ 285,676

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of Lease Liability	Future minimum lease payments under the leases are as follows: Year ending Operating Leases Remainder of 2021 $ 131,033 2022 182,249 2023 98,417 Total lease payments 411,699 Less: Imputed interest/present value discount (16,512 ) Present value of lease liabilities 395,187 Less: Current portion (165,757 ) $ 229,430

Derivative Liability (Tables)

Derivative Liability (Tables)	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value Assumptions of Warrant Liability	The fair value of the warrant liability was determined at the following reporting dates using the Black-Scholes-Merton option pricing model and the following assumptions: Warrant Liability December 31, 2020 Stock price $ 2.49 Risk free interest rate 0.17 % Expected volatility 148 % Expected life in years 3.8 Expected dividend yield 0 % Number of warrants 10,417 Fair value of warrants $ 25,978

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Warrants Activity	A summary of the Company’s warrant activity is as follows: Shares Weighted Weighted December 31, 2020 2,132,758 $ 2.48 3.81 Granted - - - Forfeitures - - - Expirations - - - Exercised (1,647,691 ) 2.26 - March 31, 2021, all exercisable 485,067 $ 2.71 3.56
Schedule of Exercise Price of Warrants Outstanding and Exercisable	The exercise prices of warrants outstanding and exercisable as of March 31, 2021 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 160,108 $ 2.05 146,667 2.67 112,001 3.30 37,700 3.51 28,591 17.25 485,067
Schedule of Share-based Compensation, Stock Options, Activity	A summary of the Company’s stock option activity is as follows: Shares Weighted Weighted December 31, 2020 778,196 9.48 6.38 Granted 152,671 3.95 9.80 Forfeitures - - - Expirations - - - Exercised - - - March 31, 2021, outstanding 930,867 $ 8.48 6.60 March 31, 2021, exercisable 479,932 $ 10.92 4.70
Schedule of Exercise Price of Options Outstanding and Exercisable	The exercise prices of options outstanding and exercisable as of March 31, 2021 are as follows: Options Outstanding (Shares) Exercise Prices 41,667 $ 1.48 5,001 1.91 41,667 2.33 1,667 2.46 16,667 3.25 152,671 3.95 375,000 6.00 104,167 12.00 69,445 13.20 10,415 13.80 112,500 15.00 930,867
Schedule of Non Vested Restricted Common Stock Activity	The following table summarizes restricted common stock activity for the three months ended March 31, 2021: Number of shares Non-vested shares, December 31, 2020 - $ - Granted 194,338 662,412 Vested (22,917 ) (181,843 ) Forfeited - - Non-vested shares, March 31, 2021 171,421 $ 480,569

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following tables set forth our results of operations by segment: For the Three Months Ended March 31, 2021 Corporate Medical Foods and Nutraceuticals Medical Devices Total Revenue $ - $ 162,143 $ 71,154 $ 233,297 Cost of goods sold - 84,917 48,098 133,015 Gross profit - 77,226 23,056 100,282 Stock compensation expense 387,615 - - 387,615 Operating expenses 1,150,600 1,176,127 55,465 2,382,192 Loss from operations $ (1,538,215 ) $ (1,098,901 ) $ (32,409 ) $ (2,669,525 ) For the Three Months Ended March 31, 2020 Corporate Medical Foods and Nutraceuticals Medical Devices Total Revenue $ 14,744 $ 139,789 $ 91,190 $ 245,723 Cost of goods sold - 78,439 30,669 109,108 Gross profit 14,744 61,350 60,521 136,615 Stock compensation expense 503,893 - - 503,893 Operating expenses 915,552 937,123 116,269 1,968,944 Loss from operations $ (1,404,701 ) $ (875,773 ) $ (55,748 ) $ (2,336,222 ) The following tables set forth our total assets by segment. Intersegment balances and transactions have been removed: As of March 31, 2021 Corporate Medical Foods and Nutraceuticals Medical Devices Total Current assets Cash $ 43,329,674 $ - $ - $ 43,329,674 Inventories - 194,081 94,446 288,527 Other - 224,660 152,759 377,419 Total current assets 43,329,674 418,741 247,205 43,995,620 Right of use asset, net - 339,873 39,247 379,120 Property and equipment, net - 125,158 140,821 265,979 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 43,329,674 $ 945,523 $ 427,273 $ 44,702,470 As of December 31, 2020 Corporate Medical Foods and Nutraceuticals Medical Devices Total Current assets Cash $ 8,518,732 $ - $ - $ 8,518,732 Inventories - 254,879 130,093 384,972 Other - 89,333 101,846 191,179 Total current assets 8,518,732 344,212 231,939 9,094,883 Right of use asset - 374,447 44,143 418,590 Property and equipment, net - 135,641 150,035 285,676 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 8,518,732 $ 916,051 $ 426,117 $ 9,860,900

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (2,669,525)	$ (2,346,913)
Cash in operating activities	(2,420,070)	$ (1,735,410)
Cash on hand	43,329,674		$ 8,518,732
Working capital	$ 43,012,927

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Mar. 01, 2021	Jan. 02, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Reverse stock split	1-for-6 reverse split
Amount paid as deposit			$ 250,000
Research and development costs			20,608	$ 31,188
Patent costs			24,297	27,181
Fair value of warrant liabilities				0	$ 25,978
Derivative liability					25,978
Warrants issued						10,417
Accumulated deficit			(56,726,875)		$ (54,083,328)
Increase decrease in derivative warrant liability				$ (8,944)
Underwriters [Member]
Accumulated deficit		$ 25,978
Increase decrease in derivative warrant liability		$ 25,978
Sales [Member] | One Customer [Member]
Concentration risk, percentage			25.00%
Medical Foods and Nutraceuticals Segment [Member]
Concentration risk, percentage			25.00%	2.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Revenues by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues	$ 233,297	$ 245,723
Medical Foods and Nutraceuticals [Member]
Revenues	162,143	139,789
Medical Devices [Member]
Revenues	71,154	91,190
Others [Member]
Revenues		$ 14,744

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Revenue by Geographical Area (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues	$ 233,297	$ 245,723
North America [Member]
Revenues	172,140	234,354
Asia [Member]
Revenues	58,262	2,800
Europe and Other [Member]
Revenues	$ 2,895	$ 8,569

Business and Summary of Signifi

Business and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive securities excluded from computation of earnings per share	1,415,934	3,607,140
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	485,067	3,065,056
Options [Member]
Antidilutive securities excluded from computation of earnings per share	930,867	542,084

Inventories (Details Narrative)

Inventories (Details Narrative)	3 Months Ended
	Mar. 31, 2021USD ($)
Inventory Disclosure [Abstract]
Write down inventory	$ 6,000

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 57,264	$ 218,307
Finished goods	231,263	166,665
Inventory, net	$ 288,527	$ 384,972

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 19,698	$ 23,114

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property, plant and equipment, gross	$ 727,023	$ 727,023
Less accumulated depreciation and amortization	(461,045)	(441,347)
Property, plant and equipment, net	265,978	285,676
Leasehold Improvements [Member]
Property, plant and equipment, gross	103,255	103,255
Testing Equipment [Member]
Property, plant and equipment, gross	348,124	348,124
Furniture and Fixtures [Member]
Property, plant and equipment, gross	197,349	197,349
Computer Equipment [Member]
Property, plant and equipment, gross	68,460	68,460
Office Equipment [Member]
Property, plant and equipment, gross	$ 9,835	$ 9,835

Operating Leases (Details Narra

Operating Leases (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Leases [Abstract]
Lease cost	$ 45,901	$ 43,581
Right-of-use assets	379,120		$ 418,590
Amortization of right of use asset	39,470	$ 37,983
Lease liabilities	395,187		$ 434,748
Operating lease payments	$ 39,561
Weighted average remaining lease terms	2 years 2 months 30 days
Lease discount rate	4.60%

Operating Leases - Schedule of

Operating Leases - Schedule of Lease Liability (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 131,033
2022	182,249
2023	98,417
Total lease payments	411,699
Less: Imputed interest/present value discount	(16,512)
Present value of lease liabilities	395,187	$ 434,748
Less Current portion	(165,757)	(162,845)
Operating lease liability - long term	$ 229,430	$ 271,903

Payable to Former Officer (Deta

Payable to Former Officer (Details Narrative) - USD ($)	Jun. 15, 2020	Mar. 31, 2021	Dec. 31, 2020
Due to former officers		$ 67,708
Due payable to former officers description		The amount due remains accrued on our consolidated balance sheet and is payable through June 15, 2021.
Michael Favish [Member]
Former officers costs			$ 325,000
Michael Favish [Member] | Settlement Agreement [Member] | Twelve Months [Member]
Payments to former officers	$ 325,000

Derivative Warrant Liability (D

Derivative Warrant Liability (Details Narrative) - USD ($)	Jan. 02, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Apr. 09, 2019
Aggregate fair value of the warrant derivative liability			$ 0	$ 25,978
Accumulated deficit		$ (56,726,875)		(54,083,328)
Increase decrease in derivative warrant liability			$ (8,944)
Underwriters [Member]
Accumulated deficit	$ 25,978
Increase decrease in derivative warrant liability	$ 25,978
Underwriters [Member] | IPO [Member]
Warrants issued					10,417
Warrants price per share					$ 30
Aggregate fair value of the warrant derivative liability				$ 25,978

Derivative Warrant Liability -

Derivative Warrant Liability - Schedule of Fair Value Assumptions of Warrant Liability (Details) - Warrant Liability [Member]	Dec. 31, 2020USD ($)$ / sharesshares
Number of warrants | shares	10,417
Fair value of derivative warrant liability | $	$ 25,978
Stock Price [Member]
Stock price | $ / shares	$ 2.49
Risk Free Interest Rate [Member]
Warrant liability, measurement input	0.17
Expected Volatility [Member]
Warrant liability, measurement input	148
Expected Life in Years [Member]
Warrant liability, measurement input, expected life (years)	3 years 9 months 18 days
Expected Dividend Yield [Member]
Warrant liability, measurement input	0

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Apr. 15, 2021	Feb. 10, 2021	Jan. 28, 2021	Jan. 15, 2021	Jan. 08, 2021	Jan. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Exercisable price							$ 10.92
Weighted average exercise price							$ 8.48		$ 9.48
Weighted average remaining life							6 years 4 months 17 days
Shares options, granted							152,671
Stock-compensation expense							$ 387,615	$ 503,893
Number of unvested options outstanding							450,935
Number of unvested options outstanding, value							$ 911,444
Unvested options, amortized year							9 years 4 months 2 days
Aggregate intrinsic value of options outstanding							$ 43,293
Restricted Common Stock [Member]
Shares options, granted							194,338
Grant date fair value of options granted							$ 662,412
Stock-compensation expense							$ 181,843
Unvested options, amortized year							3 years 8 months 12 days
Unvested compensation							$ 480,569
General and Administrative Expense [Member]
Stock-compensation expense							$ 205,772	$ 491,568
Common Stock [Member]
Share price							$ 1
Common Stock [Member] | Michael Favish [Member]
Grant date fair value of options granted							$ 514,171
Volatility rate							119.00%
Discount rate							38.00%
Expected dividend yield							0.00%
Expected life							6 years
Stock option, exercise price per share							$ 3.95
Number of options vested							50,891
Option vesting period							2 years
Warrants [Member] | Investors [Member]
Number of warrants exercised							1,647,691
Number of common stock issued							1,647,691
Net proceeds from warrants							$ 3,568,415
Exercisable price							$ 2.17
Warrants to purchase common stock							485,067
Weighted average exercise price							$ 2.71
Weighted average remaining life							3 years 6 months 21 days
Restricted Common Stock [Member]
Number of options vested						4,167
Restricted Common Stock [Member] | Subsequent Event [Member]
Number of options vested	37,500
Restricted Common Stock [Member] | Michael Favish [Member]
Shares options, granted						152,671
Restricted Common Stock [Member] | Consultant [Member]
Number of options vested						41,667
Sales Agreement [Member ]
Sale of stock, proceeds from transaction							$ 33,623,000
Issuance cost							$ 327,000
Sales Agreement [Member ] | January 2021 1st ATM Offering [Member ]
Number of stock sold during period				2,559,834
Sale of stock, proceeds from transaction				$ 9,700,000
Sales Agreement [Member ] | January 2021 1st ATM Offering [Member ] | Maximum [Member]
Sale of stock, proceeds from transaction					$ 10,000,000
Sales Agreement [Member ] | January 2021 2nd ATM Offering [Member]
Number of stock sold during period		5,006,900
Sale of stock, proceeds from transaction		$ 24,250,000
Sales Agreement [Member ] | January 2021 2nd ATM Offering [Member] | Maximum [Member]
Sale of stock, proceeds from transaction			$ 25,000,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrants Activity (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Shares, Ending Balance	485,067
Warrants [Member]
Shares, Beginning Balance	2,132,758
Shares, Granted
Shares, Forfeitures
Shares, Expirations
Shares, Exercised	(1,647,691)
Shares, Ending Balance	485,067
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.48
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Forfeitures | $ / shares
Weighted Average Exercise Price, Expirations | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares	2.26
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 2.71
Weighted Average Remaining Contractual Term (Years), Beginning Balance	3 years 9 months 22 days
Weighted Average Remaining Contractual Term (Years), Ending Balance	3 years 6 months 21 days

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Exercise Price of Warrants Outstanding and Exercisable (Details)	Mar. 31, 2021$ / sharesshares
Warrants Outstanding and Exercisable (Shares)	485,067
Warrant One [Member]
Warrants Outstanding and Exercisable (Shares)	160,108
Exercise Prices | $ / shares	$ 2.05
Warrant Two [Member]
Warrants Outstanding and Exercisable (Shares)	146,667
Exercise Prices | $ / shares	$ 2.67
Warrant Three [Member]
Warrants Outstanding and Exercisable (Shares)	112,001
Exercise Prices | $ / shares	$ 3.30
Warrant Four [Member]
Warrants Outstanding and Exercisable (Shares)	37,700
Exercise Prices | $ / shares	$ 3.51
Warrant Five [Member]
Warrants Outstanding and Exercisable (Shares)	28,591
Exercise Prices | $ / shares	$ 17.25

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Share-based Compensation, Stock Options, Activity (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Equity [Abstract]
Shares Outstanding, Beginning Balance | shares	778,196
Shares, Granted | shares	152,671
Shares, Forfeitures | shares
Shares, Expirations | shares
Shares, Exercised | shares
Shares Outstanding, Ending Balance | shares	930,867
Shares Exercisable, Ending Balance | shares	479,932
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 9.48
Weighted Average Exercise Price, Granted | $ / shares	3.95
Weighted Average Exercise Price, Forfeitures | $ / shares
Weighted Average Exercise Price, Expirations | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	8.48
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 10.92
Weighted Average Remaining Contractual Term (Years) Outstanding, Beginning Balance	6 years 4 months 17 days
Weighted Average Remaining Contractual Term (Years), Granted	9 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	6 years 7 months 6 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	4 years 8 months 12 days

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Exercise Price of Options Outstanding and Exercisable (Details) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Options Outstanding (Shares)	930,867	778,196
Exercise Price One [Member]
Options Outstanding (Shares)	41,667
Exercise Prices	$ 1.48
Exercise Price Two [Member]
Options Outstanding (Shares)	5,001
Exercise Prices	$ 1.91
Exercise Price Three [Member]
Options Outstanding (Shares)	41,667
Exercise Prices	$ 2.33
Exercise Price Four [Member]
Options Outstanding (Shares)	1,667
Exercise Prices	$ 2.46
Exercise Price Five [Member]
Options Outstanding (Shares)	16,667
Exercise Prices	$ 3.25
Exercise Price Six [Member]
Options Outstanding (Shares)	152,671
Exercise Prices	$ 3.95
Exercise Price Seven [Member]
Options Outstanding (Shares)	375,000
Exercise Prices	$ 6
Exercise Price Eight [Member]
Options Outstanding (Shares)	104,167
Exercise Prices	$ 12
Exercise Price Nine [Member]
Options Outstanding (Shares)	69,445
Exercise Prices	$ 13.20
Exercise Price Ten [Member]
Options Outstanding (Shares)	10,415
Exercise Prices	$ 13.80
Exercise Price Elevev [Member]
Options Outstanding (Shares)	112,500
Exercise Prices	$ 15

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Non Vested Restricted Common Stock Activity (Details) - Restricted Common Stock [Member]	3 Months Ended
	Mar. 31, 2021USD ($)shares
Number of shares, Non-vested shares, December 31, 2020 | shares
Number of shares, Granted | shares	194,338
Number of shares, Vested | shares	(22,917)
Number of shares, Forfeited | shares
Number of shares, Non-vested shares, March 31, 2021 | shares	171,421
Fair value of shares, Non-vested shares, December 31, 2020 | $
Fair value of shares, Granted | $	662,412
Fair value of shares, Vested | $	(181,843)
Fair value of shares, Forfeited | $
Fair value of shares, Non-vested shares, March 31, 2021 | $	$ 480,569

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Dr. David Evans [Member]
Royalty percentage on sales	3.00%
Ceatus Media Group, LLC [Member]
Services related digital marketing	$ 22,500	$ 38,000
DWT Evans LLC [Member]
Building rent	$ 5,571	$ 5,307

Segment Reporting (Details Narr

Segment Reporting (Details Narrative)	3 Months Ended
	Mar. 31, 2021Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Reporting - Schedule of

Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue	$ 233,297	$ 245,723
Cost of goods sold	133,015	109,108
Gross profit	100,282	136,615
Stock compensation expense	387,615	503,893
Operating expenses	2,769,807	2,472,837
Loss from operations	(2,669,525)	(2,336,222)
Cash	43,329,674		$ 8,518,732
Inventories, net	288,527		384,972
Other	377,419		191,179
Total current assets	43,995,621		9,094,883
Right of use asset	379,120		418,590
Property and equipment, net	265,978		285,676
Intangible assets, net	50,000		50,000
Other	11,751		11,751
Total assets	44,702,470		9,860,900
Corporate [Member]
Revenue		14,744
Cost of goods sold
Gross profit		14,744
Stock compensation expense	387,615	503,893
Operating expenses	1,150,600	915,552
Loss from operations	(1,538,215)	(1,404,701)
Cash	43,329,674		8,518,732
Inventories, net
Other
Total current assets	43,329,674		8,518,732
Right of use asset
Property and equipment, net
Intangible assets, net
Other
Total assets	43,329,674		8,518,732
Medical Foods and Nutraceuticals [Member]
Revenue	162,143
Cost of goods sold	84,917
Gross profit	77,226
Stock compensation expense
Operating expenses	1,176,127
Loss from operations	(1,098,901)
Cash
Inventories, net	194,081		254,879
Other	224,660		89,333
Total current assets	418,741		344,212
Right of use asset	339,873		374,447
Property and equipment, net	125,158		135,641
Intangible assets, net	50,000		50,000
Other	11,751		11,751
Total assets	945,523		916,051
Medical Devices [Member]
Revenue	71,154	91,190
Cost of goods sold	48,098	30,669
Gross profit	23,056	60,521
Stock compensation expense
Operating expenses	55,465	116,269
Loss from operations	(32,409)	(55,748)
Cash
Inventories, net	94,446		130,093
Other	152,759		101,846
Total current assets	247,205		231,939
Right of use asset	39,247		44,143
Property and equipment, net	140,821		150,035
Intangible assets, net
Other
Total assets	$ 427,273		$ 426,117
Medical Foods and Nutraceuticals Segment [Member]
Revenue		139,789
Cost of goods sold		78,439
Gross profit		61,350
Stock compensation expense
Operating expenses		937,123
Loss from operations		$ (875,773)

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Mr. Scholte's [Member] - Employment Agreement [Member]	Jan. 06, 2021USD ($)
Officers compensation	$ 400,000
Description of deferred compensation arrangement	Mr. Scholtes shall be granted (i) stock options equal to 2% of the Company's issued and outstanding shares of common stock on the date of grant if the Company achieves specified performance objectives established by the Board for the Company's fiscal years ending December 31, 2021, and December 31, 2022, and (ii) additional stock options equal to either 2% or 3% of the Company's issued and outstanding shares of common stock on the date of grant if the Company meets certain financial objectives during the first five years following January 6, 2021. If Mr. Scholtes' employment is terminated by the Company without cause, as defined, if the term expires after a notice of non-renewal is delivered by the Company, or if Mr. Scholtes' employment is terminated following a change of control, as defined, Mr. Scholtes will be entitled to (a) twelve months' base salary, (b) the prorated portion of the any bonus, based on actual performance, and (c) base salary and benefits accrued through the date of termination.
Minimum [Member]
Employee benefit	$ 400,000